hu8550FF Frozen Validation Report
343 PRS models · 1,636 protein predictions · 150 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Body weight, waist, and blood sugar tendency
near-term focus
Genetics points to a strong tendency toward higher body weight and waist size, with blood sugar sensitivity but some favorable lipid and insulin-related offsets.
Full explanation
The clearest metabolic theme is a strong body-composition signal. Several independent findings point toward higher body-weight, waist, fat-distribution, and weight-change tendency.
Blood sugar biology is more mixed. Some evidence points toward higher type 2 diabetes, glucose, and long-term sugar-marker tendency, while other signals suggest more favorable insulin sensitivity, beta-cell-specific diabetes context, triglycerides, and cholesterol.
That means the useful interpretation is not simply high or low risk. The pattern is divergent: body-size genetics may create pressure, while some lipid and insulin pathways may partly buffer or redirect that pressure.
This category becomes worth discussing if real-world weight, waist size, blood sugar, energy, sleep, blood pressure, pregnancy history, or family diabetes history starts moving in the same direction. It also matters if routine labs ever show rising fasting glucose, long-term sugar markers, triglycerides, or liver enzymes.
What to watch forUse a waist- and glucose-aware lifestyle baseline: prioritize strength training, regular aerobic work, high-fiber meals, steady protein, and earlier review if weight, waist, or sugar labs trend upward.
Show technical evidence
Risk-score evidence
- body mass index: risk percentile 99.4%, coverage 97%, PGS000830.
- waist circumference: risk percentile 92.7%, coverage 95%, PGS000828.
- incident type 2 diabetes: risk percentile 97.2%, coverage 99%, PGS002779.
- two hour glucose during ogtt: risk percentile 93.9%, coverage 95%, PGS000839.
- glycated haemoglobin: risk percentile 88.7%, coverage 100%, PGS001953.
- insulin sensitivity index: risk percentile 19.4%, coverage 95%, PGS000837.
Protein pathway context
- INSL3: predicted level percentile 5.1%, R2 0.7312; pathway context only.
- PNLIPRP2: predicted level percentile 13.6%, R2 0.7241; pathway context only.
- PLB1: predicted level percentile 9.6%, R2 0.5555; pathway context only.
- APOBR: predicted level percentile 8.8%, R2 0.67; pathway context only.
Candidate variants
- Variant rs10182181 GG: snpedia_context.
- Variant rs1024889 GG: snpedia_context.
- Variant rs10937273 GG: snpedia_context.
- PCSK5 rs11144688 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
Heart, blood pressure, and vessel-wall balance
near-term focus
The heart profile is mixed: lipid genetics look partly favorable, but artery-wall, blood pressure, clotting, and structural vessel signals are still notable.
Full explanation
This section is not a simple cholesterol story. Some lipid-related signals look favorable, including lower high-cholesterol, triglyceride, and apoB-related tendency, while one high HDL-related signal adds more lipid nuance.
Against that, several cardiovascular signals point toward vessel-wall and pressure biology: coronary atherosclerosis, carotid artery-wall thickness, systolic blood pressure, aortic valve disease, larger ascending aortic diameter, and clotting tendency.
Protein and variant evidence support the idea that inflammation, vessel-wall behavior, lipid transport, and clotting may be more relevant than cholesterol alone. There is also a medication-processing finding that matters if a statin is ever considered.
This becomes worth reviewing if blood pressure, cholesterol treatment, chest symptoms, fainting, unusual shortness of breath, clot history, pregnancy-related blood pressure issues, or strong family history of early heart disease is present. It is also relevant before starting a cholesterol-lowering medicine.
What to watch forKeep routine blood pressure and lipid context in view, and flag the medication-processing result if a statin is ever prescribed.
Show technical evidence
Risk-score evidence
- hdl cholesterol: risk percentile 99.9%, coverage 97%, PGS000660.
- high cholesterol: risk percentile 3.5%, coverage 90%, PGS000936.
- triglyceride: risk percentile 3.9%, coverage 98%, PGS002287.
- apolipoprotein b: risk percentile 16%, coverage 100%, PGS001889.
- cholesterol: risk percentile 14.7%, coverage 100%, PGS001895.
- systolic blood pressure automated reading: risk percentile 81.2%, coverage 100%, PGS002009.
Protein pathway context
- IL6R: predicted level percentile 94.5%, R2 0.666; pathway context only.
- MST1: predicted level percentile 97.9%, R2 0.6781; pathway context only.
- PZP: predicted level percentile 93.8%, R2 0.5407; pathway context only.
- APOBR: predicted level percentile 8.8%, R2 0.67; pathway context only.
- MMP3: predicted level percentile 13.9%, R2 0.5052; pathway context only.
- CFHR2: predicted level percentile 2.1%, R2 0.7304; pathway context only.
Candidate variants
- CDKN2B-AS1 rs10757274 GG: context_variant.
- CDKN2A,CDKN2B rs10757278 GG: snpedia_context.
- CDKN2B-AS1 rs10757269 GG: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
Medication-response context
- SLCO1B1: Decreased Function, *15/*37; affected medicines include Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin.
Kidney, uric acid, and fluid-balance awareness
useful to review
Kidney, creatinine, urine-blood, sodium, uric acid, and gout signals cluster together, with some albumin-related nuance.
Full explanation
The kidney and fluid-balance evidence is meaningful because several related traits appear together. Chronic kidney disease, creatinine, urine-blood, urinary sodium, uric acid, and gout signals all point in a similar direction.
The pattern is not perfectly one-sided. Albumin-related urine signals add nuance, and genetics alone cannot say whether kidney function is currently normal or abnormal.
Immune-complement and tissue-repair protein context may also matter because kidney biology is strongly shaped by blood pressure, inflammation, fluid balance, and vascular health.
This category becomes worth discussing if routine labs show changes in kidney function, uric acid, urine protein, urine blood, blood pressure, swelling, kidney stones, gout-like flares, or if family history includes kidney disease.
What to watch forTreat this as a reason to be attentive to kidney and uric-acid labs when they are already being checked, especially if blood pressure, gout-like symptoms, or urine findings ever appear.
Show technical evidence
Risk-score evidence
- chronic kidney disease: risk percentile 94.8%, coverage 100%, PGS004128.
- creatinine: risk percentile 85.4%, coverage 100%, PGS001945.
- hematuria: risk percentile 97.9%, coverage 100%, PGS001863.
- sodium in urine mmol l: risk percentile 99.1%, coverage 91%, PGS000695.
- serum urate: risk percentile 85.5%, coverage 99%, PGS000126.
- gout: risk percentile 83.1%, coverage 100%, PGS004006.
Protein pathway context
- LILRB5: predicted level percentile 92.2%, R2 0.7926; pathway context only.
- CFHR2: predicted level percentile 2.1%, R2 0.7304; pathway context only.
- MST1: predicted level percentile 97.9%, R2 0.6781; pathway context only.
Gallbladder, reflux, and liver-enzyme tendency
useful to review
Gallbladder, gallstone, reflux, liver-enzyme, and functional digestive signals are prominent, while several inflammatory bowel signals are lower.
Full explanation
The digestive evidence clusters around bile flow, gallbladder biology, reflux or hernia tendency, and liver-enzyme context. Several gallbladder and biliary signals are high, and enzyme-related traits also appear.
The bowel signal is more mixed. Functional digestive and diverticular signals are present, while celiac, Crohn-related, and malabsorption signals are lower, which softens the interpretation for inflammatory bowel disease.
Digestive protein context supports metabolism and fat-digestion biology rather than pointing to a single condition. Genetics cannot say whether gallstones, reflux, liver irritation, or bowel symptoms are present.
This category becomes worth discussing if right-upper-abdominal pain after fatty meals, persistent reflux, unexplained nausea, pale stools, dark urine, abnormal liver enzymes, recurrent digestive symptoms, or family history of gallbladder disease is present.
What to watch forFavor steady meal timing, high-fiber foods, unsaturated fats, and avoiding crash dieting; review sooner if gallbladder-type pain, persistent reflux, or liver-enzyme changes appear.
Show technical evidence
Risk-score evidence
- other biliary tract disease: risk percentile 98.4%, coverage 100%, PGS001862.
- cholelithiasis and cholecystitis: risk percentile 94.6%, coverage 100%, PGS001861.
- cholecystitis: risk percentile 85%, coverage 87%, PGS000942.
- gallstones: risk percentile 84.2%, coverage 91%, PGS001256.
- gamma glutamyl transferase: risk percentile 93%, coverage 97%, PGS000817.
- aspartate aminotransferase u l: risk percentile 87.1%, coverage 92%, PGS000673.
Protein pathway context
- PNLIPRP2: predicted level percentile 13.6%, R2 0.7241; pathway context only.
- PLB1: predicted level percentile 9.6%, R2 0.5555; pathway context only.
- TREH: predicted level percentile 15.4%, R2 0.5404; pathway context only.
- MST1: predicted level percentile 97.9%, R2 0.6781; pathway context only.
Candidate variants
- Variant rs10800309 GG: snpedia_context.
- IL23R rs10889676 CC: snpedia_context.
- IL23R rs10889677 CC: snpedia_context.
Immune activation and inflammatory background
background
Immune-pathway evidence is broad and mixed, with high inflammatory and autoimmune-context signals alongside several lower allergy or autoimmune tails.
Full explanation
The immune evidence is broad rather than pointing to one specific condition. White-cell count, connective-tissue involvement, lupus, thyroid, polymyalgia, mouth-ulcer, and immune-protein signals all suggest an active immune-regulation theme.
At the same time, some allergy and autoimmune-related tails are low, including atopic eczema, allergic-rhinitis context, multiple sclerosis, sarcoidosis, and some bowel-immune traits. That makes this a mixed immune profile rather than a uniform high-risk result.
Protein evidence is unusually important here because many immune signaling, tolerance, adhesion, complement, macrophage, and antigen-presentation proteins sit at strong tails. A medication-processing result also matters if thiopurine immune medicines are ever considered.
This becomes worth discussing if there are recurrent unexplained inflammatory symptoms, thyroid changes, rashes, persistent mouth ulcers, joint or muscle pain, abnormal immune blood tests, autoimmune family history, or if immune-suppressing medication is ever being considered.
What to watch forUse this as immune-background context, and make sure medication-processing information is available before any thiopurine-type immune medicine is prescribed.
Show technical evidence
Risk-score evidence
- white blood cellcount: risk percentile 95.5%, coverage 96%, PGS003924.
- polymyalgia rheumatica: risk percentile 94%, coverage 100%, PGS001878.
- lupus: risk percentile 91%, coverage 100%, PGS001870.
- other systemic involvement of connective tissue: risk percentile 88.8%, coverage 86%, PGS000960.
- hypothyroidism: risk percentile 86.9%, coverage 100%, PGS001816.
- hayfever allergic rhinitis: risk percentile 99.5%, coverage 87%, PGS001259.
Protein pathway context
- MST1: predicted level percentile 97.9%, R2 0.6781; pathway context only.
- IL6R: predicted level percentile 94.5%, R2 0.666; pathway context only.
- CFHR2: predicted level percentile 2.1%, R2 0.7304; pathway context only.
- CD300LF: predicted level percentile 97.6%, R2 0.5333; pathway context only.
- LILRB2: predicted level percentile 3%, R2 0.5829; pathway context only.
- ICAM2: predicted level percentile 3.2%, R2 0.5536; pathway context only.
Candidate variants
- IL10 rs1800896 CT: confirmation_required.
- Variant rs10484561 TT: snpedia_context.
- Variant rs10892279 GG: snpedia_context.
- LOC101929727 rs10509540 TT: snpedia_context.
- SQRDL rs1044032 TT: snpedia_context.
Medication-response context
- TPMT: Poor Metabolizer, *3A/*3B; affected medicines include Azathioprine, Mercaptopurine, Thioguanine.
Stress sensitivity, sleep, fatigue, and headaches
useful to review
Stress, worry, mood, tiredness, daytime sleepiness, headache, and migraine signals are a strong brain-and-behavior theme.
Full explanation
The brain and daily-function signal is one of the more coherent non-metabolic themes. Stress sensitivity, worry, low enthusiasm, hurt feelings, depression-related traits, and anxiety-related traits are all high.
Sleep and energy traits sit in the same cluster. Tiredness, daytime napping, daytime dozing, and getting up in the morning appear alongside headache and migraine signals.
Neurological protein context supports this as a nervous-system pathway theme, but genetics does not mean current anxiety, depression, migraine, poor sleep, or fatigue is present.
This category becomes worth discussing if sleep quality, headaches, mood, stress tolerance, daytime sleepiness, concentration, or fatigue begins to affect work, training, relationships, or recovery. It is especially relevant if symptoms are persistent, worsening, or paired with medication decisions.
What to watch forProtect sleep regularity and recovery capacity; seek review if headaches, mood changes, anxiety, or fatigue become persistent or function-limiting.
Show technical evidence
Risk-score evidence
- neuroticism score: risk percentile 99.4%, coverage 100%, PGS001996.
- suffer from nerves: risk percentile 99.3%, coverage 90%, PGS001017.
- frequency of unenthusiasm disinterest in last 2 weeks: risk percentile 98%, coverage 89%, PGS001396.
- sensitivity hurt feelings: risk percentile 97.5%, coverage 91%, PGS001016.
- lifetime major depressive disorder: risk percentile 90.6%, coverage 98%, PGS000139.
- major depression: risk percentile 84%, coverage 98%, PGS000142.
Protein pathway context
- MDGA1: predicted level percentile 0.6%, R2 0.7077; pathway context only.
- DBH: predicted level percentile 0.7%, R2 0.6647; pathway context only.
- ADGRB3: predicted level percentile 98.2%, R2 0.597; pathway context only.
Candidate variants
- CACNA1C rs1006737 GG: snpedia_context.
- TRPM8 rs10166942 TT: snpedia_context.
- LRP1 rs11172113 TT: snpedia_context.
Eye pressure and focus traits
useful to review
Glaucoma, open-angle glaucoma, myopia, corneal, and refraction-related evidence forms a clear eye-health awareness theme.
Full explanation
The eye-related evidence is focused. Glaucoma and open-angle glaucoma signals are high, and myopia, corneal resistance, and refraction-related traits also appear.
This does not mean eye pressure is currently elevated or that glaucoma is present. It means eye structure and pressure-related genetics are prominent enough to treat routine eye care as an important context.
Variant context supports the same general area, especially around glaucoma and myopia-related biology.
This category becomes worth discussing with an eye professional if there is family history of glaucoma, changing vision, eye pain, halos, severe headaches with visual symptoms, high eye pressure, or missed routine eye exams.
What to watch forKeep routine eye exams current, especially if glaucoma family history, high eye pressure, or vision changes are relevant.
Show technical evidence
Risk-score evidence
- glaucoma: risk percentile 99.3%, coverage 100%, PGS001836.
- primary open angle glaucoma: risk percentile 86.9%, coverage 87%, PGS002741.
- myopia diagnosis: risk percentile 82.1%, coverage 100%, PGS001994.
- 3mm weak meridian: risk percentile 94.9%, coverage 93%, PGS001362.
- corneal resistance factor: risk percentile 87.5%, coverage 90%, PGS001383.
- cataract: risk percentile 16.2%, coverage 100%, PGS001837.
Candidate variants
- CDKN2B rs1063192 AA: likely_chip_artifact.
- Variant rs10089517 CC: snpedia_context.
Airway capacity and respiratory resilience
background
Lower lung-function signals and respiratory infection context align with a lung immune protein signal.
Full explanation
The respiratory signal is narrower than the metabolic or immune findings, but it is meaningful. Two lung-function measures are in low tails, and an acute lower respiratory infection signal is also present.
A lung immune protein signal adds pathway support. This points more toward airway capacity and respiratory immune resilience than toward a specific diagnosis.
Genetics cannot say whether asthma, infection vulnerability, or reduced fitness is present. It can only suggest that breathing capacity may deserve attention if real-world signs line up.
This category becomes worth discussing if there is unexplained shortness of breath, wheezing, repeated chest infections, slow recovery after respiratory illness, exercise limitation, smoking or vaping exposure, or abnormal breathing tests.
What to watch forBuild aerobic capacity gradually and pay attention to breathing limits during training or illness recovery.
Show technical evidence
Risk-score evidence
- forced expiratory volume in 1 second best measure: risk percentile 96.3%, coverage 100%, PGS001918.
- lung function: risk percentile 93%, coverage 92%, PGS001237.
- unspecified acute lower respiratory infection: risk percentile 80.8%, coverage 85%, PGS000925.
Protein pathway context
- SFTPD: predicted level percentile 86.3%, R2 0.5378; pathway context only.
Blood count and clotting background
useful to review
Platelet, white-cell, red-cell distribution, low hemoglobin-related, and clotting signals create a mixed blood-count theme.
Full explanation
The blood-count evidence is mixed but meaningful. Platelet count, white-cell count, red-cell distribution, clotting, and lower hemoglobin or hematocrit-related signals appear together.
This does not identify a blood disorder. Blood counts can move for many reasons, including hydration, iron status, inflammation, infection, menstrual blood loss, medications, and lab variability.
Protein and variant context adds support around blood, vascular, and immune-cell biology, which is why the finding is kept as a separate background theme.
This category becomes worth discussing if routine blood counts are repeatedly abnormal, if there is unexplained bruising or clotting history, heavy menstrual bleeding, unusual fatigue with low iron markers, recurrent infections, or family history of clotting or blood disorders.
What to watch forTreat routine blood-count results as useful context if fatigue, bruising, clot history, heavy bleeding, or repeated abnormal labs ever appear.
Show technical evidence
Risk-score evidence
- platelet count: risk percentile 94.7%, coverage 96%, PGS003932.
- white blood cellcount: risk percentile 95.5%, coverage 96%, PGS003924.
- red blood celldistribution width: risk percentile 90%, coverage 100%, PGS001908.
- haemoglobin concentration: risk percentile 1.4%, coverage 92%, PGS001400.
- haematocrit percentage: risk percentile 5.3%, coverage 100%, PGS001925.
- immature reticulocyte fraction: risk percentile 11.6%, coverage 100%, PGS001930.
Protein pathway context
- APOBR: predicted level percentile 8.8%, R2 0.67; pathway context only.
- PZP: predicted level percentile 93.8%, R2 0.5407; pathway context only.
- ICAM2: predicted level percentile 3.2%, R2 0.5536; pathway context only.
Candidate variants
- Variant rs11104870 TT: snpedia_context.
- RCL1 rs10758658 GG: snpedia_context.
- ATP2B4 rs10900585 TT: snpedia_context.
Skin and sun-related cancer tendency
background
Skin cancer and sunburn-related genetics are notable, with pigmentation context adding practical nuance.
Full explanation
The skin evidence clusters around sun response and skin cancer tendency. Non-melanoma skin cancer, basal-cell cancer, melanoma, and childhood sunburn signals are all present.
Pigmentation context adds nuance because appearance-related genetics can influence sun sensitivity, but it does not replace real-world skin type, sun exposure, mole count, or dermatology history.
This is a prevention-oriented category. It does not mean skin cancer is present.
This category becomes worth discussing if there is personal or family history of melanoma or non-melanoma skin cancer, many moles, changing lesions, intense sun exposure, tanning-bed use, severe sunburn history, or uncertainty about skin checks.
What to watch forUse consistent sun protection and treat changing or unusual skin lesions as a reason for prompt dermatology review.
Show technical evidence
Risk-score evidence
- non melanoma skin cancer: risk percentile 94.3%, coverage 89%, PGS001040.
- basal cell carcinoma: risk percentile 89.3%, coverage 100%, PGS003416.
- childhood sunburn: risk percentile 89.3%, coverage 87%, PGS001257.
- skin melanoma: risk percentile 81.6%, coverage 98%, PGS003745.
- hair colour dark brown: risk percentile 16.5%, coverage 91%, PGS001095.
Candidate variants
- TYR rs1042602 CC: snpedia_context.
- MC1R rs1110400 TT: snpedia_context.
Gynecologic and hormone-responsive tissue context
background
A strong benign uterine-tissue signal appears with estradiol and hormone-related context, while endometrial cancer tail evidence is lower.
Full explanation
The gynecologic evidence is centered on benign uterine-tissue tendency and hormone-responsive biology. A very high benign uterine neoplasm signal is paired with estradiol and hormone-family protein context.
There is also ovarian-cancer variant context, while endometrial cancer tail evidence is lower. That combination should be treated as mixed background, not as a cancer conclusion.
Because sex metadata is female, this category is relevant to gynecologic history, bleeding patterns, pelvic symptoms, fertility history, and routine care context.
This becomes worth discussing if there is heavy or changing menstrual bleeding, pelvic pressure, unexplained pelvic pain, anemia, known fibroids, fertility concerns, abnormal imaging, or strong family history of gynecologic cancers.
What to watch forUse this as gynecologic context if bleeding, pelvic symptoms, anemia, imaging findings, or family history make it relevant.
Show technical evidence
Risk-score evidence
- benign neoplasm of uterus: risk percentile 99.4%, coverage 100%, PGS001813.
- estradiol 212 pmol l: risk percentile 88.7%, coverage 88%, PGS001182.
- endometrial cancer: risk percentile 12.5%, coverage 96%, PGS002737.
Protein pathway context
- INSL3: predicted level percentile 5.1%, R2 0.7312; pathway context only.
- PZP: predicted level percentile 93.8%, R2 0.5407; pathway context only.
Candidate variants
- LINC00824 rs10088218 GG: snpedia_context.
- ZNF483 rs10980926 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
Joints, connective tissue, and bone loading
background
Bone-density evidence looks relatively favorable, while hip, foot, connective-tissue, and inflammatory joint-muscle signals are higher.
Full explanation
The musculoskeletal pattern is mixed. Bone-density evidence looks relatively favorable, and osteoporosis-related evidence is lower, which is reassuring for bone-strength context.
The offset is that hip arthrosis, foot-shape, connective-tissue, fibroblastic, polymyalgia, and systemic connective-tissue signals are higher. Protein context also points toward tissue structure and matrix remodeling.
This matters most for training load, injury patterns, joint pain, and recovery, not as a diagnosis of arthritis or a connective-tissue disorder.
This category becomes worth discussing if hip, foot, back, tendon, or widespread muscle-joint symptoms become persistent, if mobility changes, if inflammatory stiffness appears, or if training repeatedly causes joint flares rather than normal soreness.
What to watch forPrefer progressive strength, mobility, and low-impact conditioning; adjust load early if hip, foot, tendon, or inflammatory joint symptoms appear.
Show technical evidence
Risk-score evidence
- heel quantitative ultrasound index direct entry: risk percentile 95.5%, coverage 92%, PGS000952.
- heel bone mineral densityt score automated: risk percentile 5.200000000000003%, coverage 92%, PGS001037.
- osteoporosis: risk percentile 18.1%, coverage 100%, PGS001883.
- coxarthrosis arthrosis of hip: risk percentile 95.3%, coverage 88%, PGS000967.
- hallux valgus: risk percentile 87.5%, coverage 100%, PGS001881.
- fibroblastic disorders: risk percentile 80.3%, coverage 81%, PGS001031.
Protein pathway context
- TNN: predicted level percentile 88.4%, R2 0.5604; pathway context only.
- MMP3: predicted level percentile 13.9%, R2 0.5052; pathway context only.
Candidate variants
- PXMP4 rs1074683 GG: snpedia_context.
- PCSK5 rs11144688 GG: snpedia_context.
- ZNF483 rs10980926 GG: snpedia_context.
Brain research-context findings
background
Brain-region and white-matter research findings are interesting background only, not a medical conclusion.
Full explanation
Some brain imaging research scores are notable, including white-matter and several brain-region models. These models are included as research context, not as a diagnosis or a prediction that a brain condition is present.
The most useful interpretation is that brain-structure research signals add background to the broader stress, sleep, fatigue, and headache theme. Neurological protein context also supports keeping this visible.
Because these traits are not routine clinical risk scores, they should not be used alone for medical decisions.
This category becomes worth discussing only if there are real neurological changes, new severe headaches, seizures, weakness, cognitive changes, major balance changes, abnormal imaging, or a clinician is already evaluating neurological symptoms.
What to watch forTreat this as background research context unless real neurological symptoms, abnormal imaging, or clinical evaluation make it relevant.
Show technical evidence
Risk-score evidence
- total volume of white matter hyperintensities: risk percentile 91.6%, coverage 87%, PGS001534.
- volume of caudate: risk percentile 4.4%, coverage 89%, PGS001543.
- volume of pallidum: risk percentile 6.4%, coverage 88%, PGS001631.
- volume of thalamus: risk percentile 8.2%, coverage 89%, PGS001637.
- volume of putamen: risk percentile 10%, coverage 88%, PGS001636.
- volume of white matter: risk percentile 14.5%, coverage 87%, PGS001641.
Protein pathway context
- MDGA1: predicted level percentile 0.6%, R2 0.7077; pathway context only.
- DBH: predicted level percentile 0.7%, R2 0.6647; pathway context only.
- ADGRB3: predicted level percentile 98.2%, R2 0.597; pathway context only.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C19
RAPID METABOLIZER
*1/*17
Affected drugs: Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
TPMT
POOR METABOLIZER
*3A/*3B
Affected drugs: Azathioprine, Mercaptopurine, Thioguanine
SLCO1B1
DECREASED FUNCTION
*15/*37
Affected drugs: Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.